rbd003

Robert B. Den, MD

Contact Dr. Den

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6702
(215) 955-0412 fax

Most Recent Peer-reviewed Publications

  1. Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade Prostate Cancer[Figure presented]
  2. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer
  3. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy
  4. Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle
  5. Comparison between adjuvant and early-salvage postprostatectomy radiotherapy for prostate cancer with adverse pathological features
  6. Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer
  7. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer
  8. Therapeutic challenge with a CDK 4/6 inhibitor induces an RB-dependent SMAC-mediated apoptotic response in non–small cell lung cancer
  9. Current perspectives on bone metastases in castrate-resistant prostate cancer
  10. Utilizing 10-Year Results From the American Board of Radiology Clinical Examination to Identify Areas for Programmatic Improvement
  11. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer
  12. Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study
  13. Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017
  14. Process Mapping and Time Study to Improve Efficiency of New Procedure Implementation for High-Dose Rate Prostate Brachytherapy
  15. Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities
  16. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup
  17. Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy
  18. The role of genomic techniques in predicting response to radiation therapy
  19. The Role of Genomic Techniques in Predicting Response to Radiation Therapy
  20. Increasing faculty participation in resident education and providing cost-effective self-assessment module credit to faculty through resident-generated didactics